반응식
NO.[C:3]([O:7][C:8]([N:10]1[CH2:15][CH2:14][CH:13]([CH2:16][O:17]S(C)(=O)=O)[CH2:12][CH2:11]1)=[O:9])([CH3:6])([CH3:5])[CH3:4].[NH2:22][C@@H:23]([CH2:28]O)[CH2:24][CH2:25][CH2:26][CH3:27]>>[C:3]([O:7][C:8]([N:10]1[CH2:15][CH2:14][CH:13]([CH2:16][O:17][CH2:28][C@H:23]([NH2:22])[CH2:24][CH2:25][CH2:26][CH3:27])[CH2:12][CH2:11]1)=[O:9])([CH3:6])([CH3:5])[CH3:4]참가 물질
4
실험 절차
Using amino alcohol alkylation method A, but adding 1.1 equivalents of 4-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl ester instead of 1 equivalent, (R)-norleucinol (400 mg, 3.4 mmol) afforded, after purification (SiO2: 7:3:1 hexane:EtOAc:isopropyl amine), 195 mg (18%) of the title compound.
후처리
- customafforded
- customafter purification (SiO2: 7:3:1 hexane:EtOAc:isopropyl amine), 195 mg (18%) of the title compound
출처 및 근거
- ORD 기록
- ord-24de82dae18941629b383ae8ee4ce543
- 출처 데이터셋
- uspto-grants-2008_09
- 특허 번호
- US07427632B2
연결된 노트
불러오는 중…